ReviewJournal of the Endocrine Society2026

Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications.

Emma Boretti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.